Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $24.98 and last traded at $24.85, with a volume of 3700 shares changing hands. The stock had previously closed at $24.23.
Analyst Ratings Changes
Several equities research analysts have issued reports on CPRX shares. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Bank of America restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reiterated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $32.29.
Read Our Latest Report on CPRX
Catalyst Pharmaceuticals Trading Down 1.4 %
The stock has a market cap of $2.97 billion, a PE ratio of 20.71, a PEG ratio of 3.31 and a beta of 0.84. The firm has a fifty day simple moving average of $22.62 and a two-hundred day simple moving average of $21.76.
Insider Activity at Catalyst Pharmaceuticals
In other news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.
Institutional Trading of Catalyst Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 5.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock worth $244,000 after buying an additional 580 shares during the period. Bank of Montreal Can grew its position in Catalyst Pharmaceuticals by 6.2% during the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after acquiring an additional 875 shares during the last quarter. Rhumbline Advisers increased its stake in Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock worth $6,518,000 after purchasing an additional 952 shares during the period. Handelsbanken Fonder AB lifted its position in Catalyst Pharmaceuticals by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after purchasing an additional 1,000 shares during the last quarter. Finally, PDT Partners LLC boosted its stake in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock valued at $431,000 after purchasing an additional 1,030 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.
About Catalyst Pharmaceuticals
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Further Reading
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
